Indeed, more than 44.44% of carriers harbor BRCA1-c.211dupA or BRCA2-1310_1313deAAGA mutations which highlights the importance of screening these mutations in the treatment workflow of cases with early onset or strong family history of breast cancer. Here, BRCA2 is linked to breast carcinoma.